1형 당뇨병 치료제 시장 : 인슐린 유형, 투여 형태, 투여 경로, 치료 단계, 유통 채널, 최종 사용자, 환자 연령층별 - 세계 시장 예측(2026-2032년)

The Type 1 Diabetes Drug Market is projected to grow by USD 39.07 billion at a CAGR of 9.32% by 2032.

The type 1 diabetes drug market is anchored by lifelong insulin replacement, expanding use of insulin analogs, and a rising clinical focus on disease-modifying therapies that address autoimmune beta-cell destruction. Verified epidemiology underscores the commercial and public health need: CDC data show that about 2 million people in the United States live with type 1 diabetes, including more than 300,000 children and adolescents, while global research published in The Lancet estimates millions of people worldwide are affected.

Demand is shaped by earlier diagnosis, pediatric incidence growth in several regions, broader access to continuous glucose monitoring and automated insulin delivery, and payer pressure for therapies that reduce severe hypoglycemia, diabetic ketoacidosis, and long-term complications. The market is also moving beyond glycemic control toward immune intervention, exemplified by U.S. FDA approval of teplizumab to delay stage 3 type 1 diabetes in eligible patients aged 8 years and older.

Transformative Shifts in the Type 1 Diabetes Drug Landscape

The most important shift in the type 1 diabetes drug landscape is the transition from insulin-only management toward a continuum that includes prevention, delay, precision dosing, and complication reduction. Rapid-acting and long-acting insulin analogs remain essential, while biosimilar and follow-on insulin products are increasing price competition and improving formulary flexibility in major markets.

At the same time, immune-modifying drugs, beta-cell preservation strategies, stem-cell-derived islet replacement, and encapsulation technologies are reshaping R&D priorities. Regulatory agencies are increasingly open to clinically meaningful endpoints such as delaying disease onset, reducing insulin dependency, preserving C-peptide, and improving time in range, which is shifting investment toward therapies that can change the natural history of type 1 diabetes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across type 1 diabetes drug discovery, clinical development, and real-world disease management. AI models are used to analyze immunologic biomarkers, genetic risk scores, electronic health records, clinical trial datasets, and glucose data to identify patients at risk of progression and support more efficient trial recruitment.

In commercial care pathways, AI-enabled insulin decision support and automated insulin delivery algorithms can improve glucose control when integrated with CGM and pump ecosystems. For drug developers, AI strengthens pharmacovigilance, adherence analytics, and comparative effectiveness research, helping demonstrate outcomes that payers increasingly require for reimbursement and long-term access.

Key Regional Insights Across Major Markets

North America remains the most advanced region for type 1 diabetes drugs, led by the United States, where high diagnosis rates, specialty endocrinology networks, continuous glucose monitoring adoption, and reimbursement for advanced diabetes technologies support uptake of premium insulin analogs and immune-therapy innovation. Canada shows strong clinical guideline alignment and public health support, although provincial reimbursement variation influences access to insulin formulations, diabetes devices, and adjunct care services.

Europe benefits from structured diabetes registries, national health systems, pediatric diabetes programs, and broad use of biosimilar insulin in cost-containment strategies. Asia-Pacific is expanding its clinical relevance as China, India, Japan, Australia, and South Korea improve screening, pediatric endocrinology capacity, reimbursement pathways, and digital diabetes management. Latin America demonstrates rising need as Brazil and Mexico expand public-sector diabetes care, though affordability and procurement consistency remain important constraints. The Middle East, particularly high-income Gulf health systems, is investing in specialty diabetes centers, digital health, and prevention programs, while Africa faces the greatest access barriers due to insulin affordability, cold-chain requirements, trained specialist shortages, and inconsistent supply across many countries.

Key Group Insights for Strategic Market Expansion

The European Union is a critical policy and reimbursement bloc for type 1 diabetes drugs because centralized regulatory pathways, evolving health technology assessment reforms, pharmacovigilance standards, and biosimilar adoption influence pricing and access across member states. The G7 concentrates advanced R&D capacity, premium treatment adoption, pediatric diabetes expertise, and payer scrutiny, making it central to evidence generation for insulin analogs, immunotherapies, beta-cell preservation, and beta-cell replacement programs.

BRICS countries represent high-volume long-term treatment expansion potential, particularly through China, India, and Brazil, where expanding healthcare coverage, domestic biologics capacity, and improving diagnosis can increase treated populations, although affordability remains a defining access issue. ASEAN markets are improving diabetes infrastructure and digital health adoption but remain price sensitive, requiring scalable insulin access models and clinician education. GCC countries are investing in specialty care, chronic disease management, and connected diabetes technologies, supporting higher adoption of advanced therapies when evidence is compelling. NATO overlap with North America and Europe reinforces high standards for supply chain resilience, regulatory quality, biologics manufacturing security, and continuity of essential insulin supply.

Key Country Insights in the Type 1 Diabetes Drug Market

The United States is the leading commercial market due to high treatment intensity, innovation adoption, strong clinical trial activity, and regulatory precedent for disease-delaying therapy. Canada, the United Kingdom, Germany, France, Italy, and Spain benefit from established endocrinology services, pediatric diabetes networks, and guideline-driven care, though reimbursement decisions are closely tied to cost-effectiveness evidence, real-world outcomes, and budget impact. Russia and Mexico present sustained demand for insulin access and affordability, with public procurement, domestic supply priorities, and distribution reliability playing significant roles.

China and India offer major long-term opportunity as diagnosis improves, healthcare investment grows, and specialist networks expand, but affordability, awareness, rural access, and availability of advanced diabetes technologies remain barriers. Japan, Australia, and South Korea show strong adoption of advanced diabetes technologies, favorable clinical infrastructure, and high standards for post-market safety monitoring. Brazil is the most important Latin American country in this set, driven by public-sector insulin access, private healthcare growth, diabetes advocacy, and increasing attention to pediatric and adolescent type 1 diabetes care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that generate measurable clinical value beyond HbA1c, including improved time in range, lower severe hypoglycemia, reduced diabetic ketoacidosis, preserved beta-cell function, delayed progression to symptomatic disease, and better quality of life. Evidence packages should integrate randomized controlled trials with real-world data from CGM, pump, claims, electronic health record, and registry sources.

Organizations should also strengthen access strategies through tiered pricing, biosimilar partnerships, patient support programs, clinician education, and cold-chain reliability in emerging markets. For innovation portfolios, the highest-value opportunities include immune modulation, beta-cell replacement, precision insulin delivery, and AI-enabled adherence and risk stratification tools that align drug benefits with payer-relevant outcomes and practical care delivery.

Research Methodology

This executive summary is based on secondary research using verified sources such as public health agencies, regulatory databases, clinical trial registries, peer-reviewed journals, diabetes association guidance, and publicly available healthcare policy documents. The analysis prioritizes evidence from organizations including the CDC, WHO, U.S. FDA, EMA, International Diabetes Federation, and leading clinical publications.

Market interpretation applies cross-validation across epidemiology, treatment guidelines, reimbursement trends, product approvals, pipeline activity, clinical endpoints, digital diabetes adoption, and regional access conditions. Insights are structured to support strategic planning for type 1 diabetes drug developers, insulin manufacturers, biosimilar entrants, medtech partners, payers, and healthcare investors without relying on market sizing, market share, or forecasting assumptions.

Conclusion

The type 1 diabetes drug market is entering a new phase in which insulin remains foundational while disease modification, digital integration, and precision care create differentiated strategic pathways. The approval of immune therapy to delay disease onset has validated a broader preventive and interventional model for type 1 diabetes treatment.

Future leadership will depend on demonstrating durable clinical outcomes, expanding equitable access, ensuring reliable insulin supply, and combining drug innovation with data-driven care delivery. Organizations that align biologic innovation, AI-enabled evidence generation, and region-specific reimbursement strategies will be best positioned in this evolving market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Type 1 Diabetes Drug Market, by Insulin Type

• 7.1. Intermediate-Acting
• 7.2. Long-Acting
• 7.3. Rapid-Acting
• 7.4. Short-Acting

8. Type 1 Diabetes Drug Market, by Delivery Mode

• 8.1. Pen
• 8.2. Pump
• 8.3. Syringe

9. Type 1 Diabetes Drug Market, by Route Of Administration

• 9.1. Subcutaneous
• 9.2. Intravenous

10. Type 1 Diabetes Drug Market, by Treatment Line

• 10.1. First-Line
• 10.2. Second-Line
• 10.3. Third-Line And Beyond

11. Type 1 Diabetes Drug Market, by Distribution Channel

• 11.1. Offline
• 11.2. Online

12. Type 1 Diabetes Drug Market, by End User

• 12.1. Clinics
• 12.2. Home Care
• 12.3. Hospitals

13. Type 1 Diabetes Drug Market, by Patient Age Group

• 13.1. Adult
• 13.2. Geriatric
• 13.3. Pediatric

14. Type 1 Diabetes Drug Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Type 1 Diabetes Drug Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Type 1 Diabetes Drug Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Adocia
• 18.2. Arecor Therapeutics PLC
• 18.3. AstraZeneca PLC
• 18.4. Biocon Limited
• 18.5. Bristol-Myers Squibb Company
• 18.6. Civica, Inc.
• 18.7. Diasome Pharmaceuticals Inc.
• 18.8. Eli Lilly and Company
• 18.9. Gan & Lee Pharmaceuticals Co., Ltd.
• 18.10. GlaxoSmithKline PLC
• 18.11. Johnson & Johnson Services Inc.
• 18.12. Lexicon Pharmaceuticals Inc.
• 18.13. Lupin Limited
• 18.14. MannKind Corporation
• 18.15. Merck & Co. Inc.
• 18.16. Mylan N.V.
• 18.17. Novartis AG
• 18.18. Novo Nordisk A/S
• 18.19. Pfizer Inc.
• 18.20. Provention Bio Inc.
• 18.21. Sandoz Group AG
• 18.22. Sanofi S.A.
• 18.23. Sun Pharmaceutical Industries Ltd.
• 18.24. Teva Pharmaceutical Industries Ltd.
• 18.25. Viatris Inc.
• 18.26. Zealand Pharma A/S